These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

60 related articles for article (PubMed ID: 12782916)

  • 1. Risk of serious extrapyramidal symptoms in patients with Parkinson's disease receiving antidepressant drugs: a pharmacoepidemiologic study comparing serotonin reuptake inhibitors and other antidepressant drugs.
    Gony M; Lapeyre-Mestre M; Montastruc JL;
    Clin Neuropharmacol; 2003; 26(3):142-5. PubMed ID: 12782916
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and tolerability of antidepressants in Parkinson's disease: A systematic review and network meta-analysis.
    Mills KA; Greene MC; Dezube R; Goodson C; Karmarkar T; Pontone GM
    Int J Geriatr Psychiatry; 2018 Apr; 33(4):642-651. PubMed ID: 29235150
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Depression in Parkinson's disease. Pharmacological characteristics and treatment.
    Tom T; Cummings JL
    Drugs Aging; 1998 Jan; 12(1):55-74. PubMed ID: 9467687
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Concomitant treatment with safinamide and antidepressant drugs: Safety data from real clinical practice.
    Pérez-Torre P; López-Sendón JL; Mañanes Barral V; Parees I; Fanjul-Arbós S; Monreal E; Alonso-Canovas A; Martínez Castrillo JC
    Neurologia (Engl Ed); 2024 May; 39(4):340-344. PubMed ID: 38616061
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Assessment of Extrapyramidal Symptoms Associated with Psychotropics Pharmacological Treatments, and Associated Risk Factors.
    Abu-Naser D; Gharaibeh S; Al Meslamani AZ; Alefan Q; Abunaser R
    Clin Pract Epidemiol Ment Health; 2021; 17():1-7. PubMed ID: 33719362
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of Antidepressants on Cardiac Events and All-Cause Mortality in Parkinson's Disease: A National Data-Linkage Study.
    Orayj K
    Neuropsychiatr Dis Treat; 2021; 17():2499-2510. PubMed ID: 34354357
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antidepressants and movement disorders: a postmarketing study in the world pharmacovigilance database.
    Revet A; Montastruc F; Roussin A; Raynaud JP; Lapeyre-Mestre M; Nguyen TTH
    BMC Psychiatry; 2020 Jun; 20(1):308. PubMed ID: 32546134
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patterns and Predictors of Depression Treatment among Older Adults with Parkinson's Disease and Depression in Ambulatory Care Settings in the United States.
    Bhattacharjee S; Vadiei N; Goldstone L; Alrabiah Z; Sherman SJ
    Parkinsons Dis; 2018; 2018():3402983. PubMed ID: 29686832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extrapyramidal symptoms after Fluoxetine.
    Dutta BK; Saha A; Nagesh IV
    Med J Armed Forces India; 2015 Jul; 71(Suppl 1):S99-S100. PubMed ID: 26265886
    [No Abstract]   [Full Text] [Related]  

  • 10. Monoamine reuptake inhibitors in Parkinson's disease.
    Huot P; Fox SH; Brotchie JM
    Parkinsons Dis; 2015; 2015():609428. PubMed ID: 25810948
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anxiety in Parkinson's disease: identification and management.
    Chen JJ; Marsh L
    Ther Adv Neurol Disord; 2014 Jan; 7(1):52-9. PubMed ID: 24409202
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drug-induced parkinsonism in the elderly: incidence, management and prevention.
    López-Sendón JL; Mena MA; de Yébenes JG
    Drugs Aging; 2012 Feb; 29(2):105-18. PubMed ID: 22250585
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The importance of drug-drug interactions as a cause of adverse drug reactions: a pharmacovigilance study of serotoninergic reuptake inhibitors in France.
    Montastruc F; Sommet A; Bondon-Guitton E; Durrieu G; Bui E; Bagheri H; Lapeyre-Mestre M; Schmitt L; Montastruc JL
    Eur J Clin Pharmacol; 2012 May; 68(5):767-75. PubMed ID: 22116460
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Drug safety of rosiglitazone and pioglitazone in France: a study using the French PharmacoVigilance database.
    Berthet S; Olivier P; Montastruc JL; Lapeyre-Mestre M
    BMC Clin Pharmacol; 2011 May; 11():5. PubMed ID: 21609444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Treatment of depression in Parkinson's disease.
    Menza M; Dobkin RD; Marin H
    Curr Psychiatry Rep; 2006 Jun; 8(3):234-40. PubMed ID: 19817075
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Information about ADRs explored by pharmacovigilance approaches: a qualitative review of studies on antibiotics, SSRIs and NSAIDs.
    Aagaard L; Hansen EH
    BMC Clin Pharmacol; 2009 Mar; 9():4. PubMed ID: 19254390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Sertraline in the treatment of depressive disorders in patients with Parkinson's disease.
    Marino S; Sessa E; Di Lorenzo G; Digangi G; Alagna A; Bramanti P; Di Bella P
    Neurol Sci; 2008 Dec; 29(6):391-5. PubMed ID: 19002650
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Drug interactions with cholinesterase inhibitors: an analysis of the French pharmacovigilance database and a comparison of two national drug formularies (Vidal, British National Formulary).
    Tavassoli N; Sommet A; Lapeyre-Mestre M; Bagheri H; Montrastruc JL
    Drug Saf; 2007; 30(11):1063-71. PubMed ID: 17973542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antidepressant treatment of veterans with Parkinson's disease and depression: analysis of a national sample.
    Chen P; Kales HC; Weintraub D; Blow FC; Jiang L; Mellow AM
    J Geriatr Psychiatry Neurol; 2007 Sep; 20(3):161-5. PubMed ID: 17712099
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of initial use of serotonergic antidepressants on antiparkinsonian drug use in levodopa-using patients.
    Arbouw ME; Movig KL; Neef C; Guchelaar HJ; Egberts TC
    Eur J Clin Pharmacol; 2007 Feb; 63(2):181-7. PubMed ID: 17200834
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.